

# Michael Schmueck-Henneresse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/461807/publications.pdf>

Version: 2024-02-01

28  
papers

1,022  
citations

516215

16  
h-index

500791

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1788  
citing authors

#	ARTICLE	IF	CITATIONS
1	Adoptive transfer of exÂvivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. <i>Molecular Therapy</i> , 2022, 30, 2298-2314.	3.7	16
2	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 52-73.	1.8	11
3	Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR TÂcells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2022, 25, 311-330.	1.8	33
4	CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. <i>Molecular Therapy</i> , 2021, 29, 32-46.	3.7	27
5	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	35
6	Cas9-directed immune tolerance in humansâ€”a model to evaluate regulatory T cells in gene therapy?. <i>Gene Therapy</i> , 2021, 28, 549-559.	2.3	28
7	Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD. <i>Frontiers in Immunology</i> , 2021, 12, 716629.	2.2	4
8	Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 751590.	1.8	10
9	The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation. <i>Scientific Reports</i> , 2020, 10, 19594.	1.6	4
10	HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients. <i>Frontiers in Immunology</i> , 2020, 11, 607918.	2.2	37
11	Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. <i>BMJ, The</i> , 2020, 371, m3734.	3.0	101
12	Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease. <i>Blood Advances</i> , 2020, 4, 2501-2515.	2.5	12
13	Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. <i>Frontiers in Immunology</i> , 2020, 11, 611638.	2.2	26
14	Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients. <i>Frontiers in Immunology</i> , 2019, 10, 1148.	2.2	9
15	The Value of a Rapid Test of Human Regulatory T Cell Function Needs to be Revised. <i>Frontiers in Immunology</i> , 2019, 10, 150.	2.2	3
16	The Treat-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome. <i>Scientific Reports</i> , 2019, 9, 19037.	1.6	5
17	High prevalence of <i>Streptococcus pyogenes</i> Cas9-reactive T cells within the adult human population. <i>Nature Medicine</i> , 2019, 25, 242-248.	15.2	280
18	Chimeric Antigen Receptor Signaling Domains Differentially Regulate Proliferation and Native T Cell Receptor Function in Virus-Specific T Cells. <i>Frontiers in Medicine</i> , 2018, 5, 343.	1.2	12

#	ARTICLE	IF	CITATIONS
19	Ex Vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. <i>Kidney International</i> , 2018, 93, 1452-1464.	2.6	20
20	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells. <i>Journal of Immunology</i> , 2017, 199, 348-362.	0.4	41
21	Peripheral Blood-Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency. <i>Journal of Immunology</i> , 2015, 194, 5559-5567.	0.4	36
22	A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. <i>Kidney International</i> , 2015, 88, 1293-1303.	2.6	25
23	The role of CD4+ T cells in BKV-specific T cell immunity. <i>Medical Microbiology and Immunology</i> , 2014, 203, 395-408.	2.6	29
24	Novel GMP-Compatible Protocol Employing an Allogeneic B Cell Bank for Clonal Expansion of Allospecific Natural Regulatory T Cells. <i>American Journal of Transplantation</i> , 2014, 14, 594-606.	2.6	60
25	Culture surface influence on T-cell phenotype and function. <i>Clinical Hemorheology and Microcirculation</i> , 2013, 55, 501-512.	0.9	3
26	Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells. <i>Journal of Immunology</i> , 2012, 188, 5189-5198.	0.4	22
27	Cytomegalovirus-Specific Regulatory and Effector T Cells Share TCR Clonality-Possible Relation to Repetitive CMV Infections. <i>American Journal of Transplantation</i> , 2012, 12, 669-681.	2.6	36
28	Adoptive T-Cell Therapy of a Lung Transplanted Patient with Severe CMV Disease and Resistance to Antiviral Therapy. <i>American Journal of Transplantation</i> , 2009, 9, 1679-1684.	2.6	90